Beacon Capital Management LLC Boosts Holdings in Stryker Corporation $SYK

Beacon Capital Management LLC boosted its position in shares of Stryker Corporation (NYSE:SYK) by 31.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 135 shares of the medical technology company’s stock after acquiring an additional 32 shares during the period. Beacon Capital Management LLC’s holdings in Stryker were worth $53,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of SYK. Goodman Advisory Group LLC acquired a new position in Stryker during the 1st quarter valued at approximately $32,000. City Holding Co. increased its stake in Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock valued at $33,000 after purchasing an additional 74 shares in the last quarter. Ridgewood Investments LLC increased its stake in Stryker by 48.4% during the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after purchasing an additional 30 shares in the last quarter. Ransom Advisory Ltd acquired a new position in Stryker during the 1st quarter valued at approximately $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in Stryker during the 1st quarter valued at approximately $40,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Up 0.1%

SYK stock opened at $368.83 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a market cap of $141.01 billion, a PE ratio of 48.85, a P/E/G ratio of 2.66 and a beta of 0.93. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The firm’s fifty day moving average is $385.71 and its 200 day moving average is $379.18.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue was up 11.1% compared to the same quarter last year. During the same period last year, the firm posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on SYK shares. Evercore ISI increased their price objective on shares of Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. Needham & Company LLC increased their price objective on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Rothschild & Co Redburn started coverage on shares of Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price objective on the stock. BTIG Research reiterated a “buy” rating on shares of Stryker in a research note on Monday, July 14th. Finally, Truist Financial set a $415.00 price objective on shares of Stryker and gave the stock a “hold” rating in a research note on Monday, August 4th. Fourteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $430.33.

Insider Buying and Selling at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.20% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.